Close

Advaxis (ADXS) Announces Increasing Focus on Neoantigen-Directed Immunotherapies, Reports Closing of Its Phase 3 AIM2CERV Study

June 27, 2019 6:53 AM EDT Send to a Friend
Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login